Speaker
Christopher Mortko
ASSOC VP BUSINESS DEVELOPMENT & LICENSING, MERCK
Kenilworth, New Jersey, United States
Christopher Mortko Ph.D., MBA is an Associate Vice President and Head of Search and Evaluation in the Business Development and Licensing organization at Merck and a member of the Business Development and Licensing leadership team.
In this role, Chris leads a team responsible for the search, scientific evaluation, and due diligence for late-stage research and development opportunities across all therapeutic areas and enabling technologies. He is a key member of Merck’s
Science, Strategy, and Business review governance committee that is responsible for decision making and deal structure/terms for business development opportunities.
Prior to joining Merck business development, Christopher was a Senior Biotechnology Equity Analyst on Wall Street, focusing on oncology, immunology, and other therapeutic areas. Earlier in his career he was a research scientist at Amgen and Merck and was involved in drug discovery and development across therapeutic areas. He currently serves as a board member for BioNJ and board observer for several early-stage biotechnology companies.
Christopher received his undergraduate education at Fordham University in New York. He received a PhD in Organic Chemistry from the University of California, Los Angeles and completed an MBA at the NYU Stern School of Business.
In this role, Chris leads a team responsible for the search, scientific evaluation, and due diligence for late-stage research and development opportunities across all therapeutic areas and enabling technologies. He is a key member of Merck’s
Science, Strategy, and Business review governance committee that is responsible for decision making and deal structure/terms for business development opportunities.
Prior to joining Merck business development, Christopher was a Senior Biotechnology Equity Analyst on Wall Street, focusing on oncology, immunology, and other therapeutic areas. Earlier in his career he was a research scientist at Amgen and Merck and was involved in drug discovery and development across therapeutic areas. He currently serves as a board member for BioNJ and board observer for several early-stage biotechnology companies.
Christopher received his undergraduate education at Fordham University in New York. He received a PhD in Organic Chemistry from the University of California, Los Angeles and completed an MBA at the NYU Stern School of Business.
Speaking In
1:00 PM - 2:00 PM
Monday, June 5
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
